| 94398-5 |
Ethyl sulfate |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Ethyl sulfate [Mass/mass] in Meconium by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/g |
|
|
|
|
|
|
DRUG/TOX |
|
94398-5 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Ethyl sulfate Mec Cfm-mCnt |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Ethanol metabolite; ethyl hydrogen sulfate; GCMS; LC/MS/MS; Mass content; Mec; Point in time; QNT; Quan; Quant; Quantitative; Random; SO4; SO4-2; Sulf; Sulfovinate; Sulfovinic acid |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
| 94399-3 |
Ethyl glucuronide |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Ethyl glucuronide [Mass/mass] in Meconium by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/g |
|
|
|
|
|
|
DRUG/TOX |
|
94399-3 |
|
Confirm |
|
|
Observation |
|
|
|
0 |
Ethyl glucuronide Mec Cfm-mCnt |
|
|
|
|
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; EtG; Ethanol metabolite; GCMS; Gluc; Glucouronide; LC/MS/MS; Mass content; Mec; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.68 |
2.68 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
| 944-9 |
C Ab |
PrThr |
Ser/Plas^Donor |
Pt |
Ord |
|
|
ACTIVE |
C Ab [Presence] in Serum or Plasma from Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
944-9 |
|
|
|
|
Observation |
|
|
|
0 |
C Ab SerPl Donr Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; BLOOD BANK; Donr; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Rh Blood Group System; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 9440-9 |
Lymphocytes.IgA/Lymphocytes |
NFr |
WBC |
Pt |
Qn |
|
|
ACTIVE |
IgA lymphocytes/Lymphocytes in Leukocytes |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
9440-9 |
|
|
|
|
Observation |
|
|
|
0 |
Lymphs IgA/lymph NFr WBC |
|
|
|
Y |
|
CELL MARKERS; Immune globulin A; Immunoglobulin A; Leukocytes; Lymp; Lymph; Lympho; Lymphocyte; Lymphs; Lymphs IgA; Lymphs%; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Surface.IgA; WBCs; White blood cells |
2.79 |
1.0i |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 94400-9 |
Protein.monoclonal |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Protein.monoclonal [Presence] in Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
94400-9 |
|
|
|
|
Both |
|
|
|
0 |
M Protein SerPl Ql |
|
|
|
|
|
Chemistry; M Protein; M-band; Monoclonal band; Monoclonal spike; M-protein; M-spike; Ordinal; Para protein; Paraprotein; Pl; Plasma; Plsm; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94401-7 |
ADRA2A gene.c.-1252G>C |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
ADRA2A gene c.-1252G>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94401-7 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
ADRA2A c.-1252G>C Geno Bld/T |
|
|
|
|
|
ADRA2A c.-1252G>C; Blood; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; NM_000681.3(ADRA2A):c.-1252G>C; Nominal; PCR; Point in time; Random; rs1800544; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94402-5 |
ANKK1 gene.c.2137G>A |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
ANKK1 gene c.2137G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94402-5 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
ANKK1 c.2137G>A Geno Bld/T |
|
|
|
|
|
ANKK1 c.2137G>A; Blood; DRD2/ANKK1 Taq1A polymorphism; Genetics; Glu713Lys; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; NM_178510.2(ANKK1):c.2137G>A (p.Glu713Lys); Nominal; PCR; Point in time; Random; rs1800497; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94403-3 |
CHRNA3 gene.c.645C>T |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
CHRNA3 gene c.645C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94403-3 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
CHRNA3 c.645C>T Geno Bld/T |
|
|
|
|
|
Blood; CHRNA3 c.645C>T; D398N; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; PCR; Point in time; Random; rs1051730; T prime; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 9441-7 |
Lymphocytes.IgD/Lymphocytes |
NFr |
WBC |
Pt |
Qn |
|
|
ACTIVE |
IgD lymphocytes/Lymphocytes in Leukocytes |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
9441-7 |
|
|
|
|
Observation |
|
|
|
0 |
Lymphs IgD/lymph NFr WBC |
|
|
|
Y |
|
CELL MARKERS; Immune globulin D; Immunoglobulin D; Leukocytes; Lymp; Lymph; Lympho; Lymphocyte; Lymphs; Lymphs IgD; Lymphs%; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Surface.IgD; WBCs; White blood cells |
2.79 |
1.0i |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 94411-6 |
DRD2 gene.c.-585A>G |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
DRD2 gene c.-585A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94411-6 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
DRD2 c.-585A>G Geno Bld/T |
|
|
|
|
|
Blood; DRD2 c.-585A>G; g.113475629T>C; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; PCR; Point in time; Random; rs1799978; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94412-4 |
EPHX1 gene.c.416A>G |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
EPHX1 gene.c.416A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94412-4 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
EPHX1 c.416A>G Geno Bld/T |
|
|
|
|
|
Blood; EPHX; EPHX1 c.416A>G; EPOX; Genetics; Heredity; Heritable; His139Arg; HYL1; Inherited; MEH; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; PCR; Point in time; Random; rs2234922; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94413-2 |
GRIK4 gene.c.83-10039T>C |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
GRIK4 gene c.83-10039T>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94413-2 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
GRIK4 c.83-10039T>C Geno Bld/T |
|
|
|
|
|
Blood; Genetics; GRIK4 c.83-10039T>C; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; PCR; Point in time; Random; rs1954787; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94414-0 |
MTHFR gene.c.677C>T & c.1298A>C |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
MTHFR gene c.677C>T and c.1298A>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94414-0 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
MTHFR c.677C>T + 1298A>C Geno Bld/T |
|
|
|
|
|
5,10-methylenetetrahydrofolate reductase gene; Blood; c.665C>T; C665T; C677T; Genetics; Heredity; Heritable; Inherited; methylenetetrahydrofolate reductase (NAD(P)H); Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; MTHFR c.677C>T; MTHFR c.677C>T + 1298A>C; NADPH; Nominal; p.A222V; p.Ala222Val; PCR; Point in time; Random; T prime; Tissue; Tissue, unspecified; Vascular risk; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94415-7 |
OPRM1 gene.c.118A>G |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
OPRM1 gene c.118A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94415-7 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
OPRM1 c.118A>G Geno Bld/T |
|
|
|
|
|
Asn40Asp; Blood; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; OPRM1 c.118A>G; PCR; Point in time; Random; rs1799971; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94416-5 |
SCN1A gene.c.603-91G>A |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
SCN1A gene.c.603-91G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94416-5 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
SCN1A c.603-91G>A Geno Bld/T |
|
|
|
|
|
Blood; EIEE6; FEB3; FEB3A; FHM3; GEFSP2; Genetics; HBSCI; Heredity; Heritable; Inherited; IVS5-91G>A; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; NAC1; Nav1.1; Nominal; PCR; Point in time; Random; rs3812718; SCN1; SCN1A c.603-91G>A; SMEI; Sodium channel protein, brain I alpha subunit gene; sodium channel, voltage gated, type I alpha subunit; Sodium channel, voltage-gated, type I, alpha polypeptide gene; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94417-3 |
SLC6A4 gene 5-HTTLPR variant |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
SLC6A4 gene 5-HTTLPR variant [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94417-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SLC6A4 5-HTTLPR Geno Bld/T |
|
|
|
|
|
5HTT; 5-HTT; 5HTTLPR; 5-HTTLPR; 5-hydroxytryptamine transporter gene; Blood; Genetics; Heredity; Heritable; hSERT; HTT; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; OCD1; PCR; Point in time; Random; Serotonin transporter gene; SERT; SERT1; SLC6A4 5-HTTLPR; solute carrier family 6 (neurotransmitter transporter), member 4; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94418-1 |
UGT2B15 gene.c.253G>T |
Geno |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
UGT2B15 gene c.253G>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.PHARMG |
|
94418-1 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
UGT2B15 c.253G>T Geno Bld/T |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLUG4; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Nominal; PCR; Point in time; Random; rs1902023; T prime; Tissue; Tissue, unspecified; UDP glucuronosyltransferase 2 family, polypeptide B15; UDPGT 2B8; UDPGT2B15; UDPGTH3; UGT2B15 c.253G>T; UGT2B8; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94419-9 |
Candida auris |
PrThr |
Isolate |
Pt |
Ord |
MS.MALDI-TOF |
|
ACTIVE |
Candida auris [Presence] in Isolate by MS.MALDI-TOF |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94419-9 |
|
MS.MALDI-TOF |
|
|
Both |
|
|
|
0 |
C auris Islt Ql MS.MALDI-TOF |
|
|
|
|
|
C auris; Cand; Candidiasis; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 9442-5 |
Lymphocytes.IgG/Lymphocytes |
NFr |
WBC |
Pt |
Qn |
|
|
ACTIVE |
IgG lymphocytes/Lymphocytes in Leukocytes |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
9442-5 |
|
|
|
|
Observation |
|
|
|
0 |
Lymphs IgG/lymph NFr WBC |
|
|
|
Y |
|
CELL MARKERS; Immune globulin G; Immunoglobulin G; Leukocytes; Lymp; Lymph; Lympho; Lymphocyte; Lymphs; Lymphs IgG; Lymphs%; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Surface.IgG; WBCs; White blood cells |
2.79 |
1.0i |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 94420-7 |
Lactobacillus crispatus+gasseri+jensenii+Gardnerella vaginalis+Atopobium vaginae rRNA |
PrThr |
Vag |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Lactobacillus crispatus+gasseri+jensenii + Gardnerella vaginalis + Atopobium vaginae rRNA [Presence] in Vaginal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94420-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
BV bacteria rRNA Vag Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; A vaginae; Amplif; Amplification; Amplified; BV bacteria; DNA NUCLEIC ACID PROBE; DNA probe; G vaginalis; Genital vaginal; Gen-Probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; ribosomal RNA; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94421-5 |
Candida glabrata RNA |
PrThr |
Vag |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida glabrata RNA [Presence] in Vaginal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94421-5 |
|
Probe.amp.tar |
|
|
Observation |
|
|
|
0 |
C glabrata RNA Vag Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C glabrata; Cand; Candidiasis; DNA NUCLEIC ACID PROBE; DNA probe; Genital vaginal; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; TMA; Torulopsis glabrata; Transcription mediated amplification; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94422-3 |
Candida albicans+dubliniensis+parapsilosis+tropicalis RNA |
PrThr |
Vag |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Candida albicans, C. dubliniensis, C. parapsilosis, and C. tropicalis RNA [Presence] in Vaginal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94422-3 |
|
Probe.amp.tar |
|
|
Observation |
|
|
|
0 |
Candida sp group RNA Vag Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C albicans; Cand; Candida sp group; Candidiasis; DNA NUCLEIC ACID PROBE; DNA probe; Genital vaginal; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; m005; m5; Microbiology; Monilia; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; Thrush; TMA; Transcription mediated amplification; Vag fld; Vag fluid; Vagina; Vaginal fluid |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94423-1 |
Lysosomal enzymes screen |
Imp |
Urine |
Pt |
Nar |
|
|
ACTIVE |
Lysosomal enzymes screen [Interpretation] in Urine Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
94423-1 |
|
|
|
|
Both |
|
|
|
0 |
Lysosomal Enzymes Scn Ur-Imp |
|
|
|
|
|
Chemistry; Enz; Enzyme; Genetics; Heredity; Heritable; Impression; Impression/interpretation of study; Impressions; Inherited; Interp; Interpretation; Lysosomal Enzymes Scn; Narrative; Point in time; Random; Report; Scn; Scr; Scrn; UA; UR; Urn |
2.73 |
2.68 |
|
|
|
|
|
|
|
|
|
|
Release 2.73: ORDER_OBS: updated for use as both order or observation; |
0 |
| 94424-9 |
Staphylococcus aureus methicillin resistance SCCmec+orfX junction |
PrThr |
Isolate/Specimen |
Pt |
Ord |
Molgen |
|
ACTIVE |
Staphylococcus aureus methicillin resistance SCCmec+orfX junction [Presence] by Molecular method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
94424-9 |
|
Molgen |
|
|
Observation |
|
|
|
0 |
MRSA SCCmec+orfX Islt/Spm Ql |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; Celbenin; Dimethoxypenicillin; ID; Infectious Disease; InfectiousDisease; Islt; Islt/Spm; Isol; Metacillin; Metin; Molecular genetics; MRSA; MRSA SCCmec+orfX; o71; Ordinal; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Resist; Resistanc; Resistant; Resistent; S aureus; Screen; Spec; Staficyn; Staph; Staphicillin; Staphylococcus cassette chromosome (SCCmec) |
2.68 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 94425-6 |
Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 E6+E7 mRNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Human papilloma virus E6+E7 mRNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
94425-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HPV E6+E7 mRNA Spec Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Genital warts; Gyn; Gynecology; HPV; HPV E6+E7; HPV E6+E7 mRNA; HPV I/H Risk 4; HPV16; HPV16 and 18; HPV16+18; HPV16+18+H Risk 12; Human papillomavirus; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; OB; ObGyn; Obstetrics; Ordinal; Other; Papilloma virus high risk; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.69 |
2.68 |
|
|
|
|
|
|
|
|
|
|
|
0 |
